Medical Affairs Congress Planning and Execution Intern jobs in United States
cer-icon
Apply on Employer Site
company-logo

Genmab · 8 hours ago

Medical Affairs Congress Planning and Execution Intern

Genmab is an international biotechnology company dedicated to improving the lives of patients through innovative antibody therapeutics. The Congress Planning and Execution Intern will support the Medical Affairs team in planning and executing scientific congresses, gaining hands-on experience in congress operations and scientific communications.

BiotechnologyHealth CareManufacturingMedical
check
Culture & Values
badNo H1Bnote

Responsibilities

Support the development of congress timelines, internal trackers, and planning documents
Assist with preparation of scientific materials and medical booth assets (e.g., posters, presentations, medical information resources)
Help coordinate onsite Medical Affairs activities such as schedules, meeting room logistics, and stakeholder communications
Support Medical Directors and MSLs in preparing scientific content for pre-congress and post-congress briefings
Collaborate with cross-functional partners (Medical Strategy, Commercial, Communications, etc.) to support the creation of CI deliverables
Participate in congress planning meetings, providing notes, action item follow-through, and project updates

Qualification

Life sciences knowledgeScientific communicationAnalytical skillsCross-functional collaborationOrganizational skillsTime-management skillsCommunication skills

Required

Currently enrolled in a bachelor's or master's program in life sciences, public health, pharmacy, biomedical sciences, or related field
Excellent organizational, time-management, and communication skills

Preferred

Strong analytical skills and interest in interpreting scientific or clinical data
Ability to work collaboratively in a cross-functional environment

Company

Genmab

twittertwittertwitter
company-logo
Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.

Funding

Current Stage
Public Company
Total Funding
$11.7B
Key Investors
Morgan Stanley Senior FundingGlaxoSmithKlineIndex Ventures
2025-11-18Post Ipo Debt· $6B
2025-09-29Post Ipo Debt· $5.5B
2010-07-01Post Ipo Equity· $134M

Leadership Team

leader-logo
Anthony Pagano
Chief Financial Officer
linkedin
leader-logo
Anthony Mancini
EVP & Chief Operating Officer
linkedin
Company data provided by crunchbase